The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer

The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer

<p>Muscle invasive bladder cancer (MIBC) has a poor prognosis. Currently, therapy consists of radical radiotherapy or cystectomy with or without chemotherapy. The average age of patients with MIBC is high and older patients are less able to tolerate surgery or chemoradiation due to their impai...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awdur:	Groselj, B
Awduron Eraill:	Kiltie, A
Fformat:	Traethawd Ymchwil
Iaith:	English
Cyhoeddwyd:	2014
Pynciau:	Oncology Biology

Eitemau Tebyg

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression
gan: Groselj, B, et al.
Cyhoeddwyd: (2013)

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.
gan: Groselj, B, et al.
Cyhoeddwyd: (2013)

Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair
gan: Groselj, B, et al.
Cyhoeddwyd: (2013)

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.
gan: Groselj, B, et al.
Cyhoeddwyd: (2013)

Histone Deacetylases and Their Potential as Targets to Enhance Tumour Radiosensitisation
gan: Jennifer Antrobus, et al.
Cyhoeddwyd: (2022-03-01)

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
gan: Paillas, S, et al.
Cyhoeddwyd: (2020)

Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
gan: Groselj, B, et al.
Cyhoeddwyd: (2017)

Identification of novel strategies to radiosensitise tumour cells
gan: Anbalagan, S
Cyhoeddwyd: (2014)

Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation
gan: Lourenço, J
Cyhoeddwyd: (2024)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
gan: Lin Xiao, et al.
Cyhoeddwyd: (2022-05-01)

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
gan: Sharma, N, et al.
Cyhoeddwyd: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
gan: Monica Phimmachanh, et al.
Cyhoeddwyd: (2020-10-01)

The HDAC Inhibitor Panobinostat Promotes Expression of Delta 133p53 Variants in TP53 Wild-type Bladder Cancer Cells
gan: Groselj, B, et al.
Cyhoeddwyd: (2012)

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
gan: AGM Mostofa, et al.
Cyhoeddwyd: (2021-12-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
gan: Masumeh Sanaei, et al.
Cyhoeddwyd: (2019-01-01)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
gan: Martina Korfei, et al.
Cyhoeddwyd: (2018-01-01)

Acetylation and Histone Deacetylase Inhibitors in Cancer
gan: Madeleine S. Q. Kortenhorst, et al.
Cyhoeddwyd: (2006-01-01)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
gan: Pietro Di Fazio, et al.
Cyhoeddwyd: (2010-01-01)

Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
gan: Yukiko Hazama, et al.
Cyhoeddwyd: (2022-01-01)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
gan: Farbod Shojaei, et al.
Cyhoeddwyd: (2022-01-01)

SET7/9-mediated methylation affects oncogenic functions of histone demethylase JMJD2A
gan: Ruicai Gu, et al.
Cyhoeddwyd: (2023-10-01)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
gan: Zopf Steffen, et al.
Cyhoeddwyd: (2012-09-01)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
gan: Fengyi Guo, et al.
Cyhoeddwyd: (2022-11-01)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
gan: Bin Tu, et al.
Cyhoeddwyd: (2020-06-01)

Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer
gan: Danqi Chen, et al.
Cyhoeddwyd: (2016-01-01)

Characterisation of the histone acetyltransferase KAT7 as a novel target for radiosensitisation
gan: Bittner, M
Cyhoeddwyd: (2017)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
gan: Liebes Leonard, et al.
Cyhoeddwyd: (2007-10-01)

Histone deacetylase inhibitors in multiple myeloma
gan: Sarah Deleu, et al.
Cyhoeddwyd: (2009-06-01)

The application of histone deacetylases inhibitors in glioblastoma
gan: Rui Chen, et al.
Cyhoeddwyd: (2020-07-01)

Antidepressant Actions of Histone Deacetylase Inhibitors
gan: Haggarty, Stephen J., et al.
Cyhoeddwyd: (2010)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
gan: Felix Orben, et al.
Cyhoeddwyd: (2022-05-01)

Dietary fibre manipulation as a potential endogenous mechanism of radiosensitisation in bladder cancer
gan: Then, CK
Cyhoeddwyd: (2022)

Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
gan: Fabian B. Kraft, et al.
Cyhoeddwyd: (2023-02-01)

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
gan: Eduardo Cepeda Cañedo, et al.
Cyhoeddwyd: (2021-02-01)

Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models
gan: Yinglin Wu, et al.
Cyhoeddwyd: (2022-12-01)

A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60
gan: Rahul Kumar, et al.
Cyhoeddwyd: (2022-07-01)

Translational development of MyD88 as a biomarker for selecting patients with lymphoma responsive to histone deacetylase inhibitors
gan: Sheikh, S
Cyhoeddwyd: (2017)

Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
gan: Ana Vuletić, et al.
Cyhoeddwyd: (2023-12-01)

Role of histone deacetylases and their inhibitors in neurological diseases
gan: Li-Ying Zhang, et al.
Cyhoeddwyd: (2024-10-01)

Histone Deacetylase Inhibitors from Marine Invertebrates
gan: Claudio Luparello, et al.
Cyhoeddwyd: (2020-11-01)